Comparison of naïve and central memory derived CD8+ effector cell engraftment fitness and function following adoptive transfer

X Wang, CLW Wong, R Urak, E Taus, B Aguilar… - …, 2016 - Taylor & Francis
X Wang, CLW Wong, R Urak, E Taus, B Aguilar, WC Chang, A Mardiros, LE Budde…
Oncoimmunology, 2016Taylor & Francis
abstract Human CD8+ effector T cells derived from CD45RO+ CD62L+ precursors enriched
for central memory (TCM) precursors retain the capacity to engraft and reconstitute
functional memory upon adoptive transfer, whereas effectors derived from CD45RO+
CD62L− precursors enriched for effector memory precursors do not. Here we sought to
compare the engraftment fitness and function of CD8+ effector T cells derived from
CD45RA+ CD62L+ precursors enriched for naïve and stem cell memory precursors …
Abstract
Human CD8+ effector T cells derived from CD45RO+CD62L+ precursors enriched for central memory (TCM) precursors retain the capacity to engraft and reconstitute functional memory upon adoptive transfer, whereas effectors derived from CD45RO+CD62L precursors enriched for effector memory precursors do not. Here we sought to compare the engraftment fitness and function of CD8+ effector T cells derived from CD45RA+CD62L+ precursors enriched for naïve and stem cell memory precursors (TN/SCM) with that of TCM. We found that cytotoxic T cells (CTLs) derived from TCM transcribed higher levels of CD28, FOS, INFγ, Eomesodermin (Eomes), and lower levels of BCL2L11, maintained higher levels of phosphorylated AKT, and displayed enhanced sensitivity to the proliferative and anti-apoptotic effects of γ-chain cytokines compared to CTLs derived from TN/SCM. Higher frequencies of CTLs derived from TCM retained CD28 expression and upon activation secreted higher levels of IL-2. In NOD/Scid IL-2RγCnull mice, CD8+ TCM derived CTLs engrafted to higher frequencies in response to human IL-15 and mounted robust proliferative responses to an immunostimulatory vaccine. Similarly, CD8+ TCM derived CD19CAR+ CTLs exhibited superior antitumor potency following adoptive transfer compared to their CD8+ TN/SCM derived counterparts. These studies support the use of TCM enriched cell products for adoptive therapy of cancer.
Taylor & Francis Online